Jefferies Financial Group Weighs on Merus’ Fiscal Year 2026 Earnings (NASDAQ:MRUS)


Merus (NASDAQ:MRUS – Get a rating) – Jefferies Financial Group lowered its fiscal 2026 earnings estimate for Merus in a note to investors on Tuesday, May 10. Jefferies Financial Group analyst Raycroft now expects the biotech company to post earnings per share of $1.00 for the year, down from its previous estimate of $1.09. Merus (NASDAQ:MRUS – Get a rating) last released its quarterly results on Monday, February 28. The biotech company reported ($0.34) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($0.58) by $0.24. The company posted revenue of $14.71 million in the quarter, compared to analyst estimates of $12.39 million. Merus had a negative net margin of 135.65% and a negative return on equity of 27.26%.

A number of other analysts have also published reports on MRUS. Needham & Company LLC assumed coverage for Merus shares in a Thursday, Feb. 10 research note. They issued a “buy” rating and a price target of $45.00 for the company. BMO Capital Markets assumed coverage of Merus shares in a Friday, Feb. 11 research note. They issued an “outperform” rating and a price target of $45.00 for the company. Zacks Investment Research downgraded Merus shares from a “buy” to a “hold” rating in a Friday, March 4, research memo. StockNews.com began covering Merus shares in a report on Thursday, March 31. They issued a “hold” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating on Merus shares in a report on Tuesday. Three investment analysts gave the stock a hold rating and eight gave the company a buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $38.89.

NASDAQ:MRUS shares opened at $16.26 on Thursday. The company has a fifty-day simple moving average of $24.71 and a 200-day simple moving average of $26.70. The company has a market capitalization of $708.11 million, a PE ratio of -9.45 and a beta of 1.11. Merus has a 12-month low of $16.06 and a 12-month high of $33.09.

In other news, Executive Vice President Peter B. Silverman sold 60,000 shares of the company in a trade Thursday, March 10. The shares were sold at an average price of $26.95, for a total transaction of $1,617,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, available at the SEC website. Insiders hold 2.90% of the shares of the company.

Institutional investors and hedge funds have recently changed their positions in the company. DekaBank Deutsche Girozentrale acquired a new position in shares of Merus during the fourth quarter worth $127,000. BlackRock Inc. increased its holdings of Merus shares by 11.0% during the third quarter. BlackRock Inc. now owns 279,316 shares of the biotech company valued at $6,144,000 after acquiring an additional 27,740 shares during the period. Wellington Management Group LLP increased its holdings of Merus shares by 134.9% during the third quarter. Wellington Management Group LLP now owns 5,009,204 shares of the biotech company valued at $110,201,000 after acquiring an additional 2,876,971 shares during the period. Macquarie Group Ltd. increased its holdings of Merus shares by 104.5% during the third quarter. Macquarie Group Ltd. now owns 2,585 shares of the biotech company valued at $57,000 after acquiring 1,321 additional shares during the period. Finally, Citigroup Inc. increased its stake in Merus by 1,407.9% in the third quarter. Citigroup Inc. now owns 117,297 shares of the biotech company worth $2,581,000 after purchasing an additional 109,518 shares during the period. 85.32% of the shares are held by institutional investors.

Merus Company Profile (Get a rating)

Merus NV, a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is in Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

See also

Earnings history and estimates for Merus (NASDAQ:MRUS)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Merus right now?

Before you consider Merus, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market ripples…and Merus wasn’t on the list.

Although Merus currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Previous PaydayNow: How to Finance Small Business Equipment
Next Uno Pizzeria and Grill Introduces New Virtual Brand, Detroit Pizza Works